NrasG12D/+p53−/− MEPs are transformed to leukemia-initiating cells
| Donor cell types . | No. of donor cells . | No. of helper cells . | No. of recipient mice . | Disease diagnosis . | No. of diseased animals . | % . |
|---|---|---|---|---|---|---|
| WBM | 2.5 × 105 | 2.5 × 105 | 20 | AML and T-ALL | 20 | 100 |
| CD45+ BM | 2.5 × 105 | 2.5 × 105 | 4 | AML and T-ALL | 4 | 100 |
| HSC | 30 | 2 × 105 | 10 | AML and T-ALL | 7 | 70 |
| MPP | 30 | 2 × 105 | 12 | AML and T-ALL | 10 | 83 |
| MP | 10 000 | 2 × 105 | 15 | AML | 8 | 53 |
| GMP | 4000 | 2 × 105 | 8 | N/A | 0 | 0 |
| MEP | 2000 | 2 × 105 | 14 | AML | 10 | 71 |
| Donor cell types . | No. of donor cells . | No. of helper cells . | No. of recipient mice . | Disease diagnosis . | No. of diseased animals . | % . |
|---|---|---|---|---|---|---|
| WBM | 2.5 × 105 | 2.5 × 105 | 20 | AML and T-ALL | 20 | 100 |
| CD45+ BM | 2.5 × 105 | 2.5 × 105 | 4 | AML and T-ALL | 4 | 100 |
| HSC | 30 | 2 × 105 | 10 | AML and T-ALL | 7 | 70 |
| MPP | 30 | 2 × 105 | 12 | AML and T-ALL | 10 | 83 |
| MP | 10 000 | 2 × 105 | 15 | AML | 8 | 53 |
| GMP | 4000 | 2 × 105 | 8 | N/A | 0 | 0 |
| MEP | 2000 | 2 × 105 | 14 | AML | 10 | 71 |
Primary NrasG12D/+p53−/− mice were injected with pI-pC as described in “Materials and methods.” Various types of cells were isolated on day 12 and transplanted with helper cells (CD45.1+) into lethally irradiated mice. Mice without any diseases were monitored for at least 200 days.
BM, bone marrow; WBM, whole bone marrow.